ENDOMETRIAL CANCER STAGE II

This adverse event was reported 43 times

ENDOMETRIAL CANCER STAGE II is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 SELENIUM SULFIDE 1 0.0011
1 ECALLANTIDE 1 0.0005
2 ESTRADIOL/NORETHINDRONE ACETATE 1 0.0005
3 TELMISARTAN AND HYDROCHLOROTHIAZIDE 1 0.0004
4 CARBOXYMETHYLCELLULOSE SODIUM 1 0.0002
5 ICATIBANT ACETATE 1 0.0002
6 TOPOTECAN 1 0.0002
7 C1 ESTERASE INHIBITOR RECOMBINANT 1 0.0002
8 TOLTERODINE TARTRATE 1 0.0001
9 INDOMETHACIN 1 0.0001
See all drugs enriched for association with ENDOMETRIAL CANCER STAGE II

ENDOMETRIAL CANCER STAGE II is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Plasma Kallikrein Inhibitor [EPC] 1 0.0004
1 Progesterone [EPC] 1 0.0000
2 Androgen [EPC] 1 0.0000
3 Aromatase Inhibitor [EPC] 3 0.0000
4 Pyrimidine Synthesis Inhibitor [EPC] 1 0.0000
5 Insulin [EPC] 1 0.0000
6 Interferon beta [EPC] 4 0.0000
7 Microtubule Inhibitor [EPC] 3 0.0000
8 Parathyroid Hormone Analog [EPC] 2 0.0000
9 Progestin [EPC] 4 0.0000
See all drug classes enriched for association with ENDOMETRIAL CANCER STAGE II